Puma Biotechnology Inc (NYSE:PBYI)‘s stock had its “buy” rating restated by equities research analysts at Citigroup Inc. in a report issued on Thursday, MarketBeat Ratings reports. They presently have a $156.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $114.00. Citigroup Inc.’s price target would indicate a potential upside of 25.55% from the company’s current price.

Several other brokerages have also recently issued reports on PBYI. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 target price (down previously from $118.00) on shares of Puma Biotechnology in a research report on Thursday, August 10th. Zacks Investment Research cut Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Credit Suisse Group reissued an “outperform” rating and issued a $136.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, September 27th. Finally, BidaskClub cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. Puma Biotechnology currently has a consensus rating of “Buy” and a consensus price target of $122.89.

Puma Biotechnology (PBYI) traded up 1.02% during midday trading on Thursday, hitting $124.25. The stock had a trading volume of 778,662 shares. The stock’s 50-day moving average is $99.47 and its 200-day moving average is $72.95. Puma Biotechnology has a 1-year low of $28.35 and a 1-year high of $125.00. The stock’s market capitalization is $4.62 billion.

Puma Biotechnology (NYSE:PBYI) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.78). On average, equities research analysts anticipate that Puma Biotechnology will post ($8.62) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Puma Biotechnology’s (PBYI) Buy Rating Reiterated at Citigroup Inc.” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/05/puma-biotechnologys-pbyi-buy-rating-reiterated-at-citigroup-inc.html.

In other news, insider Alan H. Auerbach sold 13,175 shares of the company’s stock in a transaction on Thursday, July 20th. The stock was sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the transaction, the insider now owns 4,170,623 shares of the company’s stock, valued at approximately $395,083,116.79. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Richard Paul Bryce sold 1,998 shares of the company’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $94.48, for a total value of $188,771.04. Following the transaction, the senior vice president now directly owns 27,246 shares in the company, valued at approximately $2,574,202.08. The disclosure for this sale can be found here. In the last three months, insiders sold 45,173 shares of company stock worth $4,738,189. Insiders own 22.70% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Strs Ohio purchased a new position in shares of Puma Biotechnology during the 2nd quarter valued at $122,000. Cubist Systematic Strategies LLC purchased a new position in shares of Puma Biotechnology during the 2nd quarter valued at $146,000. Kazazian Asset Management LLC purchased a new position in shares of Puma Biotechnology during the 2nd quarter valued at $209,000. Teacher Retirement System of Texas purchased a new position in shares of Puma Biotechnology during the 2nd quarter valued at $211,000. Finally, Ameritas Investment Partners Inc. lifted its position in shares of Puma Biotechnology by 5.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 140 shares during the last quarter. 80.98% of the stock is currently owned by hedge funds and other institutional investors.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.